drugset / Trial / NCT04935801
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
Phase 1
Completed
26 enrolled
Gylden Pharma Ltd
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland · collabUniversity of Lausanne Hospitals · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial aims to test the safety of 2 doses of a T-cell priming specific cocktail of Dengue viruses peptides representing all 4 DENV serotypes and mounted on a gold nanoparticle. NOTE: This is the master protocol of a prospective 2-stage adaptive trial, which aims to add and test a Coronavirus vaccine candidate as well, in an identical trial design.
Timeline
- Start
- 2021-08-02
- Primary completion
- 2022-03-11
- Completion
- 2022-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PepGNP-Dengue | Unknown | 2.5 unknown | Other |
| Subject | PepGNP-Dengue | Unknown | 7.5 unknown | Other |